ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY2409021 in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01241448
Recruitment Status : Completed
First Posted : November 16, 2010
Results First Posted : April 24, 2018
Last Update Posted : April 24, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

November 12, 2010
November 16, 2010
March 24, 2018
April 24, 2018
April 24, 2018
January 2011
February 2012   (Final data collection date for primary outcome measure)
Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, 24 weeks ]
Least squares means of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline HbA1c, metformin use, visit, and visit-by-treatment interaction.
Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, 24 weeks ]
Complete list of historical versions of study NCT01241448 on ClinicalTrials.gov Archive Site
  • Change From Baseline to 24 Week Endpoint in Fasting Blood Glucose (FBG) [ Time Frame: Baseline, 24 weeks ]
    Least squares means of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in 7-point Self Monitored Glucose (SMBG) Profile [ Time Frame: Baseline, 24 weeks ]
    SMBG profiles consisted of blood glucose values collected before and 2 hours after the 3 main meals and at 0300 hours (3:00 AM). Values represent mean of values collected same time on 3 separate days within a week prior to visit. Least squares (LS) mean of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in Plasma Glucose [ Time Frame: Baseline, 24 weeks ]
    Least squares means of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in Fasting Insulin [ Time Frame: Baseline, 24 weeks ]
    Least squares (LS) mean of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in Fasting Glucagon-like Peptide 1 (GLP-1) Active and Total [ Time Frame: Baseline, 24 weeks ]
    GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. Total GLP-1 is the active GLP-1 and the Dipeptidyl Peptidase IV cleaved GLP-1 form. Least squares (LS) mean of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in Fasting Lipid Profile [ Time Frame: Baseline, 24 weeks ]
    Fasting Lipid Profile included: Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol. Least squares (LS) mean of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in Lipoprotein Subfractions-Particles (Total) [ Time Frame: Baseline, 24 weeks ]
    Subfraction included: Very Low Density Lipoprotein (VLDL) Total. Least squares mean use an analysis of covariance model. The model included baseline lipoprotein subfractions, metformin use and treatment.
  • Change From Baseline to 24 Week Endpoint in Free Fatty Acids [ Time Frame: Baseline, 24 weeks ]
    Least squares mean use an analysis of covariance model. The model included baseline free fatty acid, metformin use and treatment.
  • Change From Baseline to 24 Week Endpoint Indices in Insulin Sensitivity Using Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) [ Time Frame: Baseline, 24 weeks ]
    HOMA-IR is a computer model (based on HOMA2) which uses fasting plasma insulin and glucose concentrations to estimate insulin resistance (HOMA-IR) as a proportion reference population (normal young adults). The normal reference population with normal function was indexed to 1.0. Higher values indicate increased insulin resistance. Least squares means of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint Indices in Beta-cell Function Using HOMA-B [ Time Frame: Baseline, 24 week ]
    HOMA-B is a computer model (based on HOMA-2) that uses fasting plasma insulin and glucose concentrations to estimate steady state pancreatic beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. Higher values indicate greater beta cell function. Least squares (LS) mean of the change from baseline is from a mixed-model repeated measures analysis (MMRM). The model included terms for treatment group, baseline value, metformin use, visit, and visit-by-treatment interaction.
  • Change From Baseline to 24 Week Endpoint in Weight [ Time Frame: Baseline, 24 weeks ]
    Least squares means were adjusted for baseline weight, metformin use, visit, treatment and visit by treatment interaction.
  • Population Pharmacokinetics: Apparent Clearance (CL/F) of LY2409021 [ Time Frame: Baseline up to 26 weeks ]
    Population pharmacokinetic parameter apparent clearance (CL/F) is the apparent volume of the body fluid cleared of the drug per unit of time and was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.
  • Population Pharmacokinetics: Apparent Volume of Distribution of LY2409021 [ Time Frame: Baseline up to 26 weeks ]
    Population pharmacokinetic parameter, apparent volume of distribution (V/F) is a theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. Apparent volume of distribution (V/F) was estimated by modeling of LY2409021 plasma concentration data from all LY2409021 groups.
  • The Percentage of Participants Experiencing a Hypoglycemic Episode [ Time Frame: Baseline through 24 weeks ]
    A hypoglycemic episode is any event during which typical symptoms of hypoglycemia are observed or when the measured plasma glucose concentration is less than or equal to 70 milligrams per deciliter (mg/dL) [3.9 millimoles per liter (mmol/L)].
  • The 30-Day Adjusted Rate of Hypoglycemic Episodes [ Time Frame: Baseline through 24 weeks ]
    A hypoglycemic episode is any event during which typical symptoms of hypoglycemia are observed or when the measured plasma glucose concentration is less than or equal to 70 milligrams per deciliter (mg/dL) [3.9 millimoles per liter (mmol/L)]. 30-day adjusted rate=(total number of episodes between 2 time intervals/number of days between intervals) X 30 days. Outcome measure was not analyzed due to the limited number of hypoglycemic events observed.
  • Change From Baseline to 24 Week Endpoint in Fasting Blood Glucose (FBG) [ Time Frame: Baseline, 24 weeks ]
  • Change From Baseline to 24 Week Endpoint in 7-point Self Monitored Glucose (SMBG) Profile [ Time Frame: Baseline, 24 weeks ]
  • Change From Baseline to 24 Week Endpoint in Plasma Glucose [ Time Frame: Baseline, 24 weeks ]
  • Change From Baseline to 24 Week Endpoint in Fasting Insulin [ Time Frame: Baseline, 24 weeks ]
  • Change from baseline to 24 week endpoint in fasting GLP-1 active and total [ Time Frame: Baseline, 24 weeks ]
  • Change From Baseline to 24 Week Endpoint in Fasting Lipid Profile [ Time Frame: Baseline, 24 weeks ]
  • Change from baseline to 24 week endpoint in lipoprotein subfractions [ Time Frame: Baseline, 24 weeks ]
  • Change From Baseline to 24 Week Endpoint in Free Fatty Acids [ Time Frame: Baseline, 24 weeks ]
  • Change from baseline to 24 week endpoint indices in insulin sensitivity using HOMA-IR [ Time Frame: Baseline, 24 weeks ]
  • Change From Baseline to 24 Week Endpoint Indices in Beta-cell Function Using HOMA-B [ Time Frame: Baseline, 24 week ]
  • Change From Baseline to 24 Week Endpoint in Weight [ Time Frame: Baseline, 24 weeks ]
  • Population pharmacokinetics [ Time Frame: Baseline up to 26 weeks ]
  • The incidence of hypoglycemic episodes [ Time Frame: Over 24 weeks ]
  • The rate of hypoglycemic episodes [ Time Frame: Over 24 weeks ]
Not Provided
Not Provided
 
A Study of LY2409021 in Patients With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of LY2409021 in Patients With Type 2 Diabetes Mellitus
LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is designed to compare LY2409021 given alone or given in combination with metformin against placebo the change in hemoglobin A1c after a 24-week treatment period.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: LY2409021
    Administered Orally
  • Drug: Placebo
    Administered Orally
  • Placebo Comparator: Placebo
    Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
    Intervention: Drug: Placebo
  • Experimental: 2.5 mg LY2409021
    Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
    Intervention: Drug: LY2409021
  • Experimental: 10 mg LY2409021
    Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
    Intervention: Drug: LY2409021
  • Experimental: 20 mg LY2409021
    Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
    Intervention: Drug: LY2409021
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care. 2016 Jul;39(7):1241-9. doi: 10.2337/dc15-1643. Epub 2015 Dec 17. Erratum in: Diabetes Care. 2017 Jun;40(6):808.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
263
260
March 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a diagnosis of Type 2 diabetes mellitus according to the World Health Organization (WHO) diagnostic criteria
  • Are women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause.
  • Are male patients using a reliable method of birth control during the study and until 3 months after the last dose of study medication.
  • Are being treated with either diet and exercise alone, or with diet and exercise in combination with metformin. Metformin therapy must have been stable and unchanged for at least 3 months prior to screening and at a dose of at least 1000 milligram per day (mg/day).
  • Have a hemoglobin A1c (HbA1c) value of 7.0% to 10.5%, inclusive.
  • Have a body mass index (BMI) between 25 to 45 kilogram per meter squared (kg/m^2), inclusive.

In the opinion of the investigator, are capable and willing to:

  • Perform self-monitoring of blood glucose
  • Complete a study diary as required for this protocol
  • Maintain consistent dietary, physical activity, and sleeping patterns throughout the duration of the study
  • Comply with treatment regimens
  • Have given written informed consent to participate in this study in accordance with local regulations and the Ethical Review Board (ERB) governing the study site.

Exclusion Criteria:

  • Have more than 1 episode of severe hypoglycemia (defined as an event during which the patient requires the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) within 6 months prior to screening, or have a current diagnosis of hypoglycemia unawareness.
  • Have had two or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening.
  • Have gastrointestinal disease that may significantly impact gastric emptying or motility or have undergone gastric bypass or gastric banding surgery.
  • Have had a previous diagnosis of pancreatitis.
  • Have New York Heart Association (NYHA) class II, III, or IV symptoms of heart failure
  • Have a history of myocardial infarction, unstable angina, or a coronary revascularization procedure within 6 months of screening.
  • Have a history of supraventricular tachycardia, ventricular tachycardia, or other cardiac arrhythmia.
  • Have a history of transient ischemic attack (TIA) or stroke within 6 months of screening.
  • Have poorly controlled hypertension (systolic blood pressure greater than or equal to 150 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg) as determined by the mean of three separate measurements.
  • Show evidence of labile blood pressure, including symptomatic postural hypotension.
  • Have any abnormality of the ECG that would impact patient safety or data interpretation.
  • Show clinical signs or symptoms of liver disease, or liver function tests (LFTs; aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 2.5 times upper limit of normal (ULN) as determined by the central laboratory at screening.
  • Have a current or previous diagnosis of Gilbert's disease.
  • Have previous or current diagnosis of Hepatitis B or C
  • Have a serum creatinine >2 milligrams per deciliter (mg/dL) or, in patients being treated with metformin, a serum creatinine above (or creatinine clearance below) what is approved in the metformin product labeling in the respective country.
  • Show evidence of uncorrected hypothyroidism or hyperthyroidism based on clinical evaluation and/or an abnormal thyroid stimulating hormone result as determined by the central laboratory at screening; patients receiving dose-stable thyroid replacement therapy for at least 3 months prior to screening will be allowed to participate in the study.
  • Have any other abnormal laboratory value that, in the opinion of the investigator, precludes the patient from participation in the study. Laboratory abnormalities consistent with type 2 diabetes mellitus and all other eligibility criteria are acceptable: for example, abnormalities of blood glucose, hemoglobin A1c (HbA1c), urinary glucose, and urinary protein (with a range of trace to 1+ on dipstick).
  • Have a currently suspected or treated malignancy, or are in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
  • Have a personal or family history of pancreatic neoplasia.
  • Have non-fasting triglycerides >600 mg/dL.
  • Use or have used insulin or GLP-1 agonists (for more than 1 week within the 3-month period prior to screening), or any oral antihyperglycemic medication (OAM) other than metformin within the 3-month period prior to screening.
  • Currently use or intend to use prescription or over-the-counter medications, including herbal supplements, to promote weight loss or to regulate blood glucose.
  • Have current chronic (>2 weeks) systemic glucocorticoid therapy (excluding ocular topical, other topical, inhaled preparations) or have received such therapy within 8 weeks prior to screening.
  • Currently use hyperglycemia-causing agents, hypoglycemia-causing agents (other than metformin), class II and III antiarrythmic agents, agents that reduce gastrointestinal motility, central nervous system stimulants (with the exception of caffeinated beverages), fibrates, and niacin greater than or equal to 1 grams per day (gm/day).
  • Have an average weekly alcohol intake that exceeds 2 units per day for males and 1 unit per day for females (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 milliliters (mL) of wine; 1.5 oz or 45 milliliter (mL) of distilled spirits).
  • Currently use drugs with a narrow therapeutic index (for example, digoxin, lithium, phenytoin, theophylline, and warfarin).
  • Currently use drugs that are known to prolong the QT interval.
  • Currently use or intend to use potent inhibitors of CYP3A, which include but are not limited to atazanavir, indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, and telithromycin.
  • Have previously completed or withdrawn from this study or any other study investigating LY2409021.
  • Have known allergies to LY2409021 or related compounds.
  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or unapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have any other condition such as alcohol abuse, drug abuse, or psychiatric disorder that may affect the ability to participate in the trial.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   Italy,   Puerto Rico,   Romania,   Slovakia,   Spain,   United States
Poland
 
NCT01241448
13031
I1R-MC-GLBG ( Other Identifier: Eli Lilly and Company )
No
Not Provided
Not Provided
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-4559) or 1-317-615-4559 Mon - Fri 9 Am - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP